Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Department of Pharmacy, The Ottawa Hospital, Ottawa, Ontario, Canada.
PLoS One. 2020 Apr 17;15(4):e0231883. doi: 10.1371/journal.pone.0231883. eCollection 2020.
A current assessment of case reports of possible drug-induced pancreatitis is needed. We systematically reviewed the case report literature to identify drugs with potential associations with acute pancreatitis and the burden of evidence supporting these associations.
A protocol was developed a priori (PROSPERO CRD42017060473). We searched MEDLINE, Embase, the Cochrane Library, and additional sources to identify cases of drug-induced pancreatitis that met accepted diagnostic criteria of acute pancreatitis. Cases caused by multiple drugs or combination therapy were excluded. Established systematic review methods were used for screening and data extraction. A classification system for associated drugs was developed a priori based upon the number of cases, re-challenge, exclusion of non-drug causes of acute pancreatitis, and consistency of latency.
Seven-hundred and thirteen cases of potential drug-induced pancreatitis were identified, implicating 213 unique drugs. The evidence base was poor: exclusion of non-drug causes of acute pancreatitis was incomplete or poorly reported in all cases, 47% had at least one underlying condition predisposing to acute pancreatitis, and causality assessment was not conducted in 81%. Forty-five drugs (21%) were classified as having the highest level of evidence regarding their association with acute pancreatitis; causality was deemed to be probable or definite for 19 of these drugs (42%). Fifty-seven drugs (27%) had the lowest level of evidence regarding an association with acute pancreatitis, being implicated in single case reports, without exclusion of other causes of acute pancreatitis.
Much of the case report evidence upon which drug-induced pancreatitis associations are based is tenuous. A greater emphasis on exclusion of all non-drug causes of acute pancreatitis and on quality reporting would improve the evidence base. It should be recognized that reviews of case reports, are valuable scoping tools but have limited strength to establish drug-induced pancreatitis associations.
CRD42017060473.
需要对可能的药物引起的胰腺炎的病例报告进行当前评估。我们系统地审查了病例报告文献,以确定与急性胰腺炎有潜在关联的药物以及支持这些关联的证据负担。
预先制定了方案(PROSPERO CRD42017060473)。我们搜索了 MEDLINE、Embase、Cochrane 图书馆和其他来源,以确定符合急性胰腺炎公认诊断标准的药物引起的胰腺炎病例。排除了由多种药物或联合治疗引起的病例。使用既定的系统评价方法进行筛选和数据提取。根据病例数量、再挑战、排除急性胰腺炎的非药物原因以及潜伏期的一致性,预先制定了关联药物的分类系统。
确定了 713 例潜在的药物引起的胰腺炎,涉及 213 种独特的药物。证据基础很差:所有病例均未完全或未充分报告排除急性胰腺炎的非药物原因,47%的病例有至少一种易患急性胰腺炎的基础疾病,81%的病例未进行因果关系评估。45 种药物(21%)被归类为与急性胰腺炎关联的最高证据水平;其中 19 种药物(42%)的因果关系被认为是可能或确定的。57 种药物(27%)与急性胰腺炎关联的证据水平最低,这些药物仅涉及单个病例报告,未排除其他急性胰腺炎的原因。
药物引起的胰腺炎关联的大部分病例报告证据都很薄弱。更加强调排除所有非药物引起的急性胰腺炎的原因和高质量报告将改善证据基础。应该认识到,病例报告的综述是有价值的范围界定工具,但在确定药物引起的胰腺炎关联方面的强度有限。
CRD42017060473。